A Validated Stability Indicating RP-HPLC Method for the Determination of Aprepitant in Bulk and Pharmaceutical Dosage Forms

A stability indicating HPLC assay method has been developed and validated for the estimation of aprepitant in bulk and pharmaceutical dosage forms. A RP-HPLC isocratic separation was achieved on C 18 column (250X4.6 mm i.d., 5µm) utilizing a mobile phase comprising of methanol and water in the ratio of 90: 10(v/v) and the eluents from the column were detected using a variable wavelength detector at 220 nm. The stress testing of aprepitant was carried out under acidic, alkaline hydrolysis, oxidation and thermal degradation (dry heat) conditions and apripitant was well resolved from its degradation products with good resolution. The proposed method has permitted the quantification of aprepitant in the linearity range of 1-100µg/ml and the flow rate was maintained at 1ml/min. The column was maintained at ambient temperature and the complete separation was achieved for aprepitant with all degradation products in an overall analytical run time of approximately 15 min and it was eluting at approximately 4.4 min. The retention times of aprepitant and rimonabant hydrochloride (IS) were found to be 4.383 min and 5.783 min, respectively. The limit of detection and limit quantification were found to be 0.130µg/ml and 0.395µg/ml, respectively. The percentage recovery was found to be in between 99.56 to 101.5 and the % RSD of system and method precision was found to be 1.20 and 0.561, respectively. The percentage amount of marketed commercial brand of aprepitant was found to be 99.97. The method was found to be suitable for the routine quality control analysis of aprepitant in bulk drug and formulation as well as for the stability indicating studies. The method was validated as per ICH guidelines.

[1]  T. Satyanarayana,et al.  The Estimation of Aprepitant in Capsules Dosage forms by RP-HPLC. , 2009 .

[2]  J. Barrett,et al.  A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research. , 2009, Journal of Pharmaceutical and Biomedical Analysis.

[3]  S. Walker,et al.  Stability of an extemporaneous oral liquid aprepitant formulation , 2009, Supportive Care in Cancer.

[4]  P. Skrdla,et al.  An HPLC chromatographic reactor approach for investigating the hydrolytic stability of a pharmaceutical compound. , 2006, Journal of pharmaceutical and biomedical analysis.

[5]  B. Matuszewski,et al.  Simultaneous determination of Aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. , 2004, Journal of pharmaceutical and biomedical analysis.

[6]  B. Matuszewski,et al.  Determination of a novel substance P inhibitor in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization mass spectrometric detection using single and triple quadrupole detectors. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  Gunnar Antoni,et al.  Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant , 2004, Biological Psychiatry.

[8]  Yadan W. Chen,et al.  Characterization and quantitation of aprepitant drug substance polymorphs by attenuated total reflectance fourier transform infrared spectroscopy. , 2003, Analytical chemistry.

[9]  A. H. Ponfoort [Drugs in the future]. , 1971, Tijdschrift voor ziekenverpleging.